Breaking News

Clinilabs Selected for Phase I Study of Rosacea

Clinilabs has been selected to conduct a Phase I study of an investigational medication for the treatment of Rosacea.

Clinilabs has been selected to conduct a Phase I study of an investigational medication for the treatment of Rosacea. Enrollment for this study is expected to begin in mid-September.

Dr. Gary Zammit, president and chief executive officer of Clinilabs, said, “The award of this project represents a significant achievement for the organization as it builds upon its experience as a specialty service provider to expand into new therapeutic areas.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters